This is a preprint.
Reversal of pulmonary veno-occlusive disease phenotypes by inhibition of the integrated stress response
- PMID: 38076809
- PMCID: PMC10705277
- DOI: 10.1101/2023.11.27.568924
Reversal of pulmonary veno-occlusive disease phenotypes by inhibition of the integrated stress response
Update in
-
Reversal of pulmonary veno-occlusive disease phenotypes by inhibition of the integrated stress response.Nat Cardiovasc Res. 2024 Jul;3(7):799-818. doi: 10.1038/s44161-024-00495-z. Epub 2024 Jul 9. Nat Cardiovasc Res. 2024. PMID: 39196173 Free PMC article.
Abstract
Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension arising from EIF2AK4 gene mutations or mitomycin C (MMC) administration. The lack of effective PVOD therapies is compounded by a limited understanding of the mechanisms driving the vascular remodeling in PVOD. We show that the administration of MMC in rats mediates the activation of protein kinase R (PKR) and the integrated stress response (ISR), which lead to the release of the endothelial adhesion molecule VE-Cadherin in the complex with Rad51 to the circulation, disruption of endothelial barrier, and vascular remodeling. Pharmacological inhibition of PKR or ISR attenuates the depletion of VE-Cadherin, elevation of vascular permeability, and vascular remodeling instigated by MMC, suggesting potential clinical intervention for PVOD. Finally, the severity of PVOD phenotypes was increased by a heterozygous BMPR2 mutation that truncates the carboxyl tail of BMPR2, underscoring the role of deregulated BMP signal in the development of PVOD.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources